Apremilast

Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. Chief Editor: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, January 2015.


Apremilast - codes and concepts
open

Apremilast (Otezla®; Celgene, New Jersey, USA) is an oral small molecule inhibitor of the enzyme phosphodiesterase 4, which plays an important role in chronic inflammation associated with psoriasis.

What is apremilast used for?

In September 2014, the US Food and Drug Administration (FDA) approved the use of apremilast in patients with plaque psoriasis. It was approved for use in New Zealand in psoriasis in November 2016.

Apremilast was approved for treatment of plaque psoriasis in patients:

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for apremilast for:

It has been reported to be particularly effective in palmoplantar psoriasis.

How does apremilast work in psoriasis?

  • Psoriasis plaque formation is thought to be caused by dysregulated immune activity within the skin.
  • This dysregulation can lead to an increase in production of proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-17, and IL-23 which promote chronic inflammation of the epidermis and proliferation of keratinocytes.
  • These changes result in redness, itching, epidermal thickening and scaly plaques.
  • PDE4 is the predominant intracellular cyclic adenosine monophosphate (cAMP)-degrading enzyme within a variety of inflammatory cells, including eosinophils, neutrophils, macrophages, T cells, and monocytes.
  • PDE4 degrades cAMP into its inactive form AMP, thus allowing these immune cells to produce elevated levels of proinflammatory cytokines and decreased levels of anti-inflammatory cytokines.
  • Apremilast is an inhibitor of PDE4 and prevents the degredation of cAMP to AMP, suppressing the production of proinflammatory cytokines including tumour necrosis factor TNF-α, IL-17, and interferon (IFN)-γ and promoting the production of anti-inflammatory mediators such as IL-10.

How is apremilast administered?

The recommended dose of apremilast is 30 mg twice daily. To reduce the risk of gastrointestinal symptoms the recommended dose is titrated according to the following schedule:

Day 1: 10 mg in morning
Day 2: 10 mg in morning and 10 mg in evening
Day 3: 10 mg in morning and 20 mg in evening
Day 4: 20 mg in morning and 20 mg in evening
Day 5: 20 mg in morning and 30 mg in evening
Day 6 and thereafter: 30 mg twice daily

For patients with severe renal impairment the recommended dose is 30 mg once daily, titrated using the morning schedule only, as listed above.

  • Apremilast can be taken with or without food.
  • Tablets should not be crushed, split, or chewed.

Link to key clinical-trial evidence about apremilast...

Potential drug interactions with apremilast

  • Apremilast should not be administered together with drugs that increase the activity of hepatic cytochrome P450 enzymes, eg, rifampicin, phenobarbital, carbamazepine, phenytoin.
  • Co-administration with rifampicin has resulted in a reduction of circulating apremilast with a loss of efficacy.
  • No significant pharmacokinetic interactions were observed when 30 mg of oral apremilast was administered with oral contraceptives, ketoconazole, or methotrexate.

What are the adverse effects with apremilast

Apremilast is well tolerated. No monitoring or testing is required.

  • Diarrhoea (17%), nausea (17%), and upper respiratory tract infection (9%) were the most commonly reported adverse reactions in clinical trials in 1426 adult patients with moderate to severe plaque psoriasis treated with apremilast compared with placebo.
  • The most common adverse reactions leading to discontinuation of apremilast were nausea (1.6%), diarrhoea (1.0%), and headache (0.8%).

Use in pregnancy

  • The incidences of malformations and pregnancy loss in human pregnancies have not been established for apremilast.
  • Apremilast should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • In animal embryo-fetal development studies, the administration of apremilast to cynomolgus monkeys during organogenesis resulted in dose-related increases in abortion/embryo-fetal death at dose exposures 2.1-times the maximum recommended human therapeutic dose.

Use in nursing mothers

It is not known whether apremilast or its metabolites are present in human milk.

Paediatric use

The safety and effectiveness of apremialst have not been established in patients less than 18 years of age.

Geriatric use

No overall differences were observed in efficacy and safety of apremilast in elderly subjects ≥65 years of age compared with those <65 years of age in clinical trials involving 1257 plaque psoriasis patients.

Renal impairment

The dose of apremialst should be reduced to 30 mg once daily in patients with severe renal impairment (creatinine clearance of less than 30 mL per minute).

Hepatic impairment

No dose adjustments of apremilast is necesary in patients with moderate and severe hepatic impairment.

Allergic reactions

Apremilast is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation.

Depression

Treatment with apremilast is associated with an increase in depression. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and if such changes occur to contact their healthcare provider.

Weight loss

Patients treated with apremilast should have their body weight monitored regularly. In clinical trials in psoriasis, weight decrease between 5%-10% of body weight occurred in 12% (96/784) of subjects treated with apremilast compared to 5% (19/382) treated with placebo.

If unexplained or clinically significant weight loss occurs, discontinuation of apremilast should be considered.

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.

Ask an online dermatologist now
Securely upload your symptoms and pictures using First Derm
(Sponsored content)

 

Related information

 

References

  • Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013; 7: 201–10. PubMed
  • Papp KA, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27: e376–83. PubMed
  • Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738–46. PubMed
  • Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95–102. PubMed
  • Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013; 12: 888–97. PubMed
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137–74. PubMed

On DermNet NZ

Other websites

Books about skin diseases

See the DermNet NZ bookstore.